BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carothers C, Birrer K, Vo M. Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series. Pharmacotherapy 2020;40:1166-71. [PMID: 33006138 DOI: 10.1002/phar.2464] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Kelleni MT. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment. SN Compr Clin Med 2021;:1-5. [PMID: 33644693 DOI: 10.1007/s42399-021-00824-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
2 Cichoż-Lach H, Michalak A. Liver injury in the era of COVID-19. World J Gastroenterol 2021; 27(5): 377-390 [PMID: 33584070 DOI: 10.3748/wjg.v27.i5.377] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
3 Parlak C, Alver Ö, Ouma CNM, Rhyman L, Ramasami P. Can the Antivirals Remdesivir and Favipiravir Work Better Jointly? In Silico Insights. Drug Res (Stuttg) 2021. [PMID: 34535038 DOI: 10.1055/a-1585-1323] [Reference Citation Analysis]
4 Liu Y, Zhou S, Xiang D, Ju L, Shen D, Wang X, Wang Y. Friend or Foe? The Roles of Antioxidants in Acute Lung Injury. Antioxidants (Basel) 2021;10:1956. [PMID: 34943059 DOI: 10.3390/antiox10121956] [Reference Citation Analysis]
5 Wu PE, Morris AM. Remdesivir for patients with COVID-19. CMAJ 2021;193:E125. [PMID: 33408097 DOI: 10.1503/cmaj.202505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Clinton JW, Kiparizoska S, Aggarwal S, Woo S, Davis W, Lewis JH. Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature. Drug Saf 2021;44:1125-49. [PMID: 34533782 DOI: 10.1007/s40264-021-01109-4] [Reference Citation Analysis]
7 Sodeifian F, Seyedalhosseini ZS, Kian N, Eftekhari M, Najari S, Mirsaeidi M, Farsi Y, Nasiri MJ. Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review. Front Med (Lausanne) 2021;8:731436. [PMID: 34616757 DOI: 10.3389/fmed.2021.731436] [Reference Citation Analysis]
8 Satsangi S, Gupta N, Kodan P. Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver. J Clin Transl Hepatol 2021;9:436-46. [PMID: 34221930 DOI: 10.14218/JCTH.2020.00174] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Ozkurt Z, Çınar Tanrıverdi E. COVID-19: Gastrointestinal manifestations, liver injury and recommendations. World J Clin Cases 2022; 10(4): 1140-1163 [DOI: 10.12998/wjcc.v10.i4.1140] [Reference Citation Analysis]
10 Hutchison AL, Pillai A. The effect of COVID-19 on liver transplantation: impact, practice patterns, therapeutics, and next steps. Curr Opin Organ Transplant 2021;26:339-45. [PMID: 33938470 DOI: 10.1097/MOT.0000000000000883] [Reference Citation Analysis]
11 McGrowder DA, Miller F, Anderson Cross M, Anderson-Jackson L, Bryan S, Dilworth L. Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. Diseases 2021;9:50. [PMID: 34287285 DOI: 10.3390/diseases9030050] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Aleem A, Mahadevaiah G, Shariff N, Kothadia JP. Hepatic manifestations of COVID-19 and effect of remdesivir on liver function in patients with COVID-19 illness. Proc (Bayl Univ Med Cent) 2021;34:473-7. [PMID: 34219928 DOI: 10.1080/08998280.2021.1885289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Cárdenas-Rodríguez N, Bandala C, Vanoye-Carlo A, Ignacio-Mejía I, Gómez-Manzo S, Hernández-Cruz EY, Pedraza-Chaverri J, Carmona-Aparicio L, Hernández-Ochoa B. Use of Antioxidants for the Neuro-Therapeutic Management of COVID-19. Antioxidants (Basel) 2021;10:971. [PMID: 34204362 DOI: 10.3390/antiox10060971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Wu PE, Morris AM. Le remdésivir chez les patients atteints de la COVID-19. CMAJ 2021;193:E495-6. [PMID: 33824151 DOI: 10.1503/cmaj.202505-f] [Reference Citation Analysis]